(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 14.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Apellis Pharmaceuticals's revenue in 2025 is $775,840,000.On average, 10 Wall Street analysts forecast APLS's revenue for 2025 to be $97,823,655,931, with the lowest APLS revenue forecast at $92,891,758,366, and the highest APLS revenue forecast at $103,330,926,882. On average, 10 Wall Street analysts forecast APLS's revenue for 2026 to be $120,593,888,022, with the lowest APLS revenue forecast at $100,000,346,992, and the highest APLS revenue forecast at $132,494,238,492.
In 2027, APLS is forecast to generate $149,001,220,838 in revenue, with the lowest revenue forecast at $131,086,597,180 and the highest revenue forecast at $161,560,774,762.